<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Naringenin blocks MAPKs phosphorylation by decreasing translocation and DNA binding of NF-κB and AP-1, which restrain the production of proinflammatory cytokines such as IL-33, TNF-α, IL-1β, and IL-6 [
 <xref ref-type="bibr" rid="CR105">105</xref>]. It has been reported that naringenin suppressed respiratory overexpression and eosinophilic airway inflammation in asthma and thus, reduced acute neutrophilic airway inflammation by blocking the NF-κB pathway [
 <xref ref-type="bibr" rid="CR106">106</xref>]. Naringenin has been found to impair replication of several viruses in human cells such as dengue, Zika and Chikungunya viruses [
 <xref ref-type="bibr" rid="CR107">107</xref>–
 <xref ref-type="bibr" rid="CR109">109</xref>] and to guarantee a significant protection against LPS-induced acute lung injuries through its anti-inflammatory, antioxidant, antinitrosative and antiapoptotic effects [
 <xref ref-type="bibr" rid="CR110">110</xref>, 
 <xref ref-type="bibr" rid="CR111">111</xref>]. Due to its strong anti-inflammatory and anti-oxidant effects, narigenin may be utilized against pneumonia companied with the spread of COVID-19.
</p>
